Heritage Pharma Announces the Launch of Felodipine Extended-Release Tablets

Eatontown, NJ, December 1, 2014. Heritage Pharmaceuticals Inc. (“Heritage”) announced the immediate availability of Felodipine extended-release tablets in 2.5, 5 and 10 mg strengths. This launch adds to Heritage’s robust portfolio of generic oral solid products. Felodipine is the AB rated generic equivalent to the calcium channel blocker drug Plendil®ⱡ. It is indicated for the treatment of hypertension. According to IMS data for the twelve-months ended September 2014, the U.S. market for Felodipine extended-release tablets approximated $31 million.

Download Press Release